Kirkland & Ellis advised Danaher Corporation (NYSE: DHR), a global science and technology innovator, on its definitive agreement with General Electric (NYSE: GE) to acquire the BioPharma division of GE Life Sciences (“GE BioPharma”) for a cash purchase price of $21.4 billion. GE Biopharma is a leading provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The transaction is subject to customary conditions and is expected to be completed in the second half of calendar year 2019.
Read the company press release
The Kirkland team was led by transactional partners Michael Brueck, Daniel Wolf and James Hu and associate Francisco Morales.